What is YBRAIN?
YBRAIN is at the forefront of developing and commercializing electronic drugs designed to alleviate depression, utilizing advanced neuroscience-based technology. The company provides a comprehensive mental health care platform that facilitates at-home treatment solutions, prioritizing user safety and convenience. Their core offerings, MINDD SCAN and MINDD STIM+, are engineered to enhance mental health care and have demonstrated efficacy through clinical trials. Ybrain's strategic focus is on serving both healthcare providers and patients seeking innovative therapeutic options.
How much funding has YBRAIN raised?
YBRAIN has raised a total of $3.5M across 1 funding round:
Series A
$3.5M
Series A (2014): $3.5M with participation from Stonebridge Capital
Key Investors in YBRAIN
Stonebridge Capital
Stonebridge Capital is an investment firm focused on providing personalized financial and investment planning, with a philosophy centered on understanding client goals to develop tailored strategies for asset protection and wealth creation.
What's next for YBRAIN?
The substantial enterprise-level funding YBRAIN has attracted indicates a strong market validation and positions the company for significant scaling and further research and development. This capital infusion is expected to accelerate the expansion of their electronic drug therapies and mental health platform, potentially leading to broader market penetration and the development of next-generation solutions. The strategic nature of the recent investment suggests a focus on enhancing Ybrain's market position and technological capabilities.
See full YBRAIN company page
